Abstract:DNA damage repair (DDR) comprises the detection and correction of alterations in the chemical structure of DNA. The dysfunction of the DDR process has been determined to have important implications for tumor carcinogenesis, malignancy progression, treatment resistance, and prognosis assessment. However, the role of the DDR process in gastric cancer (GC) remains to be fully understood. Thus, a total of 2,019 GC samples from our hospital (Harbin Medical University Cancer Hospital in china) and 12 public data sets were included in our study. In this study, single-sample gene set enrichment analysis (ssGSEA) was used to generate the DDR pathway activity profiles of 8 DDR sub-pathways and identify a DDR pathway signature by combining the DDR sub-pathway gene sets. The DDR pathway profiling’s impacts on the clinical outcomes, biological functions, genetic variants, immune heterogeneity, and treatment responses were analyzed through multidimensional genomics and clinical data. The results demonstrate that the DDR pathway profiling was clearly distinguished between tumor and normal tissues. The DDR pathway profiling reveals patient-level variations, which may contribute to explaining the high heterogeneity of human GC for the biological features and treatment outcomes. Thus, tumors with low DDR signature scores were independently correlated with shorter overall survival time and significantly associated with mesenchymal, invasion, and metastasis phenotypes. The statistical model integrating this DDR pathway signature with other clinical predictors outperforms each predictor alone for predicting overall survival in discrimination, calibration, and net clinical benefit. Moreover, low DDR signature scores were tightly associated with genome stability, characterized by low tumor mutational burden (TMB) and low fractions of genome alteration. Furthermore, this study confirms that patients with low DDR pathway signature scores might not benefit from adjuvant chemotherapy and a monoclonal antibody directed against programmed cell death-1 ligand 1 (anti-PD1) therapy. These findings highlighted that the DDR pathway profiling confers important implications for patients with GC and provides insights into the specific clinical and molecular features underlying the DDR process, which may help to facilitate clinical management.

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

Alterations of DNA damage repair in cancer: from mechanisms to applications

Alterations in DNA Damage Response and Repair Genes As Potential Biomarkers for Immune Checkpoint Blockade in Gastrointestinal Cancer

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

Advancing cancer therapy: new frontiers in targeting DNA damage response

The crosstalk between DNA-damage responses and innate immunity

DNA Damage Checkpoint Recovery and Cancer Development

DNA Damage and Activation of cGAS/STING Pathway Induce Tumor Microenvironment Remodeling

Deleterious Alterations Of Dna Damage Response And Repair (Ddr) Genes In Association With Clinical Benefit To Programmed Cell Death Protein-1 (Pd-1)/Pd Ligand 1 (Pd-L1)-Based Therapy In Esophageal Squamous Cell Carcinoma (Escc)

The Roles of DNA Damage Response Machineries in Maintaining Genome Stability&Cellular Homeo-stasis

When DNA-damage responses meet innate and adaptive immunity

Genetic vulnerabilities upon inhibition of DNA damage response

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Targeting DNA damage response pathways in cancer

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer

Genomic instability, inflammatory signaling and response to cancer immunotherapy

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Telomere-related DNA damage response pathways in cancer therapy: prospective targets